Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 748-751

  Hunter, Aimee M ^a   Cook, Ian A ^a   Leuchter, Andrew F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 78649358023     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181faa474     Document Type: Letter

References (20)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D Report. Am J Psychiatry. 2006;163:1905-1917.
2. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psych. 1994;18(2):243-261.
3. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depressionYa retrospective study. J Affect Disord. 2005;89(1-3):183-188.
4. Amsterdam JD, Williams D, Michelson D, et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology. 2009;59(4):227-233.
5. Thase ME, Rush AJ. When at first you don-t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29.
6. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment resistant depression. J Clin Psychiatry. 2003;64: 35-39.
7. Leuchter AF, Cook IA, Hunter AM, et al. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci. 2009;11(4):435-446.
8. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992;41(3):203-214.
9. Cook IA, Hunter AM, Abrams M, et al. Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Res. 2009;174(2): 152-157.
10. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders Y Patient Edition (SCID-I/P, Version 2.0 ). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
11. Hamilton M. A rating scale for depression. J Neurol Neursurg Psychiatry. 1960;23:56-62.
12. Stein DJ, Baldwin DS, Dolberg OT, et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11): 1741-1746.
13. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22(1):40-45.
14. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161(11): 2045-2049.
15. Khan A, Schwartz K, Kolts RL, et al. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry. 2007; 62(1):65-71.
16. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double blind randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
17. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
18. Posternak MA, Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J Clin Psychiatry. 2005;66(6):705-707.
19. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178: 234-241.
20. Posternak MA, Young D, Sheeran T, et al. Assessing past treatment history: test-retest reliability of the Treatment Response to Antidepressant Questionnaire. J Nerv Ment Dis. 2004;192(2):95-102.